Dr. Chantelle Thomas
speaker
1,116 appearances
2 recordings
1 series
first heard Jul 2026
last heard 30 Jul
Dr. Chantelle Thomas’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Jul 2026 with 2.
Appearances
Sorry.
One thing that I think is important to note, and I think anyone who's done psilocybin research will say, a real limitation of the research is the fact that these compounds are working so differently than, say, a classic psychotropic or an antidepressant.
because they're broadening the range of what people experience and they're actually fundamentally shifting for many people, their experience of themselves.
And that's not to say that that couldn't happen with something like Zoloft, right?
You tell yourself, I'm the kind of person that only feels this way.
And then all of a sudden you start feeling differently.
So you start asking different questions, but I think kind of the depth and profundity of which people are asking bigger questions about themselves and their conditions is just being kind of
brought up for revision in a very different way with psilocybin because you're having these longer sessions, four to six hours, I would say on average, six to eight for some people, where you're encountering experiences.
You're getting this experiential engagement with your emotions, with your history.
you're asking big questions about life death meaning purpose worthiness that are kind of emerging as a result of being in this non-ordinary state of consciousness um that fundamentally for some people can shift perspective in these ways that another way to think about it is that oftentimes when people are stuck in a condition that feels kind of limiting and rigid and just um
makes the world feel small and makes them feel small they've got very restrictive ways of thinking about the world and what's possible it's like the way they predict what's possible is very narrow whereas uh one theory about what's happening with something like psilocybin for example is it's turning down the volume on prediction and turning up the volume on experience
So that the experience that you're having in real time is somehow reshaping the story you have about what's possible, not only about the condition you're navigating, but also about you yourself.
It's kind of like a nouveau way of cognitive restructuring that's not simply about thought exercises or challenging your beliefs because you're not trying to fight a predominant thought.
You're actually moving away from thought territory altogether as the sole place where things get determined.
And moving into experience as the way that gets to dictate what the story is or what your experience is.
So that's kind of interesting and new and quite novel in terms of how we might think about something like an SSRI or an antidepressant.
Okay, so one thing I want to clarify because it's important to make this clear.
I previously talked about in the last episode about how MDMA went to try to get approval through the FDA attached to a very specific therapeutic protocol.
These other, the psilocybin that's coming from USONA and the psilocybin that's coming from Compass Pathways that's moving towards the FDA finish line, they're not attached to a specific standalone therapy.
Okay.
Showing 121–140 of 1,116 · page 7 of 56
← Previous
Next →